CBTF Programs and Research

Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

The FDA granted an orphan drug designation to herpes simplex virus type 1 (HSV-1) oncolytic virus MB-108 for malignant glioma treatment.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

An investigational formula of panobinostat called MTX110 may improve outcomes in patients with recurrent glioblastoma.

Weekly MR-Linac adaptive radiotherapy limited exposure to normal brain tissue in patients with high-grade glioma.